

MARYLAND PSYCHIATRIC SOCIETY



February 6, 2026

OFFICERS 2025-2026

Ronald F. Means, M.D.
President

Tyler Hightower, M.D.
President-Elect

Michael A. Young, M.D.
Secretary-Treasurer

Theodora G. Balis, M.D.
Council Chair

EXECUTIVE DIRECTOR

Meagan H. Floyd

COUNCIL

Benedicto R. Borja, M.D.

Mary Cutler, M.D.

Mark S. Komrad, M.D.

Stephanie Knight, M.D.

Cynthia Major Lewis, M.D.

Rachna S. Raisinghani, M.D.

Taylor Scott, M.D.

Traci J. Speed, M.D., Ph.D.

EARLY CAREER

PSYCHIATRIST COUNCILOR

Melissa Lavoie, M.D.

RESIDENT-FELLOW

MEMBER COUNCILOR

Matthew Brandt, M.D.

PAST PRESIDENTS

Jessica V. Merkel-Keller, M.D.

Carol Vidal, M.D., Ph.D.

APA ASSEMBLY

REPRESENTATIVES

Adefolake Akinsanya, M.D.

Elias K. Shaya, M.D.

Brian Zimnitzky, M.D.

MEDCHI DELEGATE

Enrique I. Oviedo, M.D.

The Honorable Pamela Beidle
Finance Committee
3 East Miller Senate Office Building
Annapolis, Maryland 21401

Oppose: Senate Bill 470: State Board of Physicians - Naturopathic Doctors - Scope of Practice, Renewals, and Professional Liability Insurance

Dear Chairwoman Beidle & Members of the Committee:

The Maryland Psychiatric Society (MPS) and the Washington Psychiatric Society (WPS) are state medical organizations whose physician members specialize in diagnosing, treating, and preventing mental illnesses, including substance use disorders. Formed more than sixty-five years ago to support the needs of psychiatrists and their patients, both organizations work to ensure available, accessible, and comprehensive quality mental health resources for all Maryland citizens and strive through public education to dispel the stigma and discrimination of those suffering from a mental illness. As the district branches of the American Psychiatric Association covering the state of Maryland, MPS/WPS represent over 1200 psychiatrists and physicians currently in psychiatric training.

MPS/WPS strongly oppose Senate Bill 470, which would significantly expand the prescribing and drug administration authority of naturopathic doctors to include Schedule III, IV, and V controlled substances. This bill presents a clear risk to public health and safety by allowing individuals without adequate medical training to prescribe and administer powerful and potentially addictive medications.

Controlled substances in Schedules III-V include drugs with well-documented risks, including abuse potential, dependence, and significant psychiatric side effects. These include ketamine (Schedule III), a dissociative anesthetic with hallucinogenic properties that has gained popularity in unregulated wellness clinics; benzodiazepines such as Xanax and Valium (Schedule IV), which carry a high risk of dependence and overdose; and codeine-containing cough syrups (Schedule V), which are frequently misused. By granting prescribing privileges to naturopaths, this bill would create a proliferation of poorly regulated clinics administering these substances without the rigorous oversight and medical safeguards required to ensure patient safety.

Unlike medical doctors, psychiatrists, or even nurse practitioners, naturopaths do not receive the necessary pharmacological training to responsibly prescribe and monitor controlled substances. Their educational programs lack the extensive clinical training required to safely assess, diagnose, and treat patients with complex medical and psychiatric conditions. The absence of formal residency training further exacerbates concerns regarding their ability to appropriately manage medications with significant risks.

Maryland has already seen an influx of unregulated ketamine clinics operating with minimal oversight. By expanding naturopathic prescribing authority, SB 470 would open the door to even more such facilities, increasing the risk of inappropriate prescribing, misuse, and patient harm. Additionally, allowing naturopaths to administer these drugs by intravenous and subcutaneous injection—without the extensive medical training required for safe administration—further endangers patient safety.

At a time when Maryland is grappling with the opioid crisis, rising rates of benzodiazepine dependence, and increasing concerns about the commercialization of psychedelic treatments, it is irresponsible to lower prescribing standards and widen access to these substances outside of appropriately trained medical professionals. For these reasons, the Maryland Psychiatric Society urges an unfavorable report on SB 470.

For these reasons, we oppose SB 470. If you have any questions regarding this testimony, please contact MPS lobbyist, Lisa Harris Jones at lisa.jones@mdlobbyist.com.

Respectfully Submitted,
The Maryland Psychiatric Society & Washington Psychiatric Society
Legislative Action Committee